348 related articles for article (PubMed ID: 33054121)
1. Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletion.
Tam CS; Robak T; Ghia P; Kahl BS; Walker P; Janowski W; Simpson D; Shadman M; Ganly PS; Laurenti L; Opat S; Tani M; Ciepluch H; Verner E; Šimkovič M; Österborg A; Trněný M; Tedeschi A; Paik JC; Kuwahara SB; Feng S; Ramakrishnan V; Cohen A; Huang J; Hillmen P; Brown JR
Haematologica; 2021 Sep; 106(9):2354-2363. PubMed ID: 33054121
[TBL] [Abstract][Full Text] [Related]
2. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial.
Tam CS; Brown JR; Kahl BS; Ghia P; Giannopoulos K; Jurczak W; Šimkovič M; Shadman M; Österborg A; Laurenti L; Walker P; Opat S; Chan H; Ciepluch H; Greil R; Tani M; Trněný M; Brander DM; Flinn IW; Grosicki S; Verner E; Tedeschi A; Li J; Tian T; Zhou L; Marimpietri C; Paik JC; Cohen A; Huang J; Robak T; Hillmen P
Lancet Oncol; 2022 Aug; 23(8):1031-1043. PubMed ID: 35810754
[TBL] [Abstract][Full Text] [Related]
3. Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study.
Xu W; Yang S; Zhou K; Pan L; Li Z; Zhou J; Gao S; Zhou D; Hu J; Feng R; Huang H; Ji M; Guo H; Huang J; Novotny W; Feng S; Li J
J Hematol Oncol; 2020 May; 13(1):48. PubMed ID: 32393328
[TBL] [Abstract][Full Text] [Related]
4. Zanubrutinib for treatment-naïve and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study.
Cull G; Burger JA; Opat S; Gottlieb D; Verner E; Trotman J; Marlton P; Munoz J; Johnston P; Simpson D; Stern JC; Prathikanti R; Wu K; Novotny W; Huang J; Tam CS
Br J Haematol; 2022 Mar; 196(5):1209-1218. PubMed ID: 34915592
[TBL] [Abstract][Full Text] [Related]
5. Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial.
Soumerai JD; Mato AR; Dogan A; Seshan VE; Joffe E; Flaherty K; Carter J; Hochberg E; Barnes JA; Hamilton AM; Abramson JS; Batlevi CL; Matasar MJ; Noy A; Owens CN; Palomba ML; Kumar A; Takvorian T; Ni A; Choma M; Friedman C; Chadha P; Simkins E; Ruiters J; Sechio S; Portman D; Ramos L; Nolet N; Mahajan N; Martignetti R; Mi J; Scorsune K; Lynch J; McGree B; Hughes S; Grieve C; Roeker LE; Thompson M; Johnson PC; Roshal M; Huang J; Biondo J; Wu Q; Jacob A; Abdel-Wahab O; Zelenetz AD
Lancet Haematol; 2021 Dec; 8(12):e879-e890. PubMed ID: 34826411
[TBL] [Abstract][Full Text] [Related]
6. Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma.
Tam CS; Quach H; Nicol A; Badoux X; Rose H; Prince HM; Leahy MF; Eek R; Wickham N; Patil SS; Huang J; Prathikanti R; Cohen A; Elstrom R; Reed W; Schneider J; Flinn IW
Blood Adv; 2020 Oct; 4(19):4802-4811. PubMed ID: 33022066
[TBL] [Abstract][Full Text] [Related]
7. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.
Stilgenbauer S; Eichhorst B; Schetelig J; Coutre S; Seymour JF; Munir T; Puvvada SD; Wendtner CM; Roberts AW; Jurczak W; Mulligan SP; Böttcher S; Mobasher M; Zhu M; Desai M; Chyla B; Verdugo M; Enschede SH; Cerri E; Humerickhouse R; Gordon G; Hallek M; Wierda WG
Lancet Oncol; 2016 Jun; 17(6):768-778. PubMed ID: 27178240
[TBL] [Abstract][Full Text] [Related]
8. Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study.
Shadman M; Flinn IW; Levy MY; Porter RF; Burke JM; Zafar SF; Misleh J; Kingsley EC; Yimer HA; Freeman B; Rao SS; Chaudhry A; Tumula PK; Gandhi MD; Manda S; Chen DY; By K; Xu L; Liu Y; Crescenzo R; Idoine A; Zhang X; Cohen A; Huang J; Sharman JP
Lancet Haematol; 2023 Jan; 10(1):e35-e45. PubMed ID: 36400069
[TBL] [Abstract][Full Text] [Related]
9. Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial.
Davids MS; Brander DM; Kim HT; Tyekucheva S; Bsat J; Savell A; Hellman JM; Bazemore J; Francoeur K; Alencar A; Shune L; Omaira M; Jacobson CA; Armand P; Ng S; Crombie J; LaCasce AS; Arnason J; Hochberg EP; Takvorian RW; Abramson JS; Fisher DC; Brown JR;
Lancet Haematol; 2019 Aug; 6(8):e419-e428. PubMed ID: 31208944
[TBL] [Abstract][Full Text] [Related]
10. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.
O'Brien S; Jones JA; Coutre SE; Mato AR; Hillmen P; Tam C; Österborg A; Siddiqi T; Thirman MJ; Furman RR; Ilhan O; Keating MJ; Call TG; Brown JR; Stevens-Brogan M; Li Y; Clow F; James DF; Chu AD; Hallek M; Stilgenbauer S
Lancet Oncol; 2016 Oct; 17(10):1409-1418. PubMed ID: 27637985
[TBL] [Abstract][Full Text] [Related]
11. An indirect comparison of acalabrutinib with and without obinutuzumab vs zanubrutinib in treatment-naive CLL.
Kittai AS; Allan JN; James D; Bridge H; Miranda M; Yong ASM; Fam F; Roos J; Shetty V; Skarbnik A; Davids MS
Blood Adv; 2024 Jun; 8(11):2861-2869. PubMed ID: 38598745
[TBL] [Abstract][Full Text] [Related]
12. Zanubrutinib Monotherapy for Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Pooled Analysis of Three Studies.
Xu W; Yang S; Tam CS; Seymour JF; Zhou K; Opat S; Qiu L; Sun M; Wang T; Trotman J; Pan L; Gao S; Zhou J; Zhou D; Zhu J; Song Y; Hu J; Feng R; Huang H; Su D; Shi M; Li J
Adv Ther; 2022 Sep; 39(9):4250-4265. PubMed ID: 35900694
[TBL] [Abstract][Full Text] [Related]
13. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL.
Tam CS; Trotman J; Opat S; Burger JA; Cull G; Gottlieb D; Harrup R; Johnston PB; Marlton P; Munoz J; Seymour JF; Simpson D; Tedeschi A; Elstrom R; Yu Y; Tang Z; Han L; Huang J; Novotny W; Wang L; Roberts AW
Blood; 2019 Sep; 134(11):851-859. PubMed ID: 31340982
[TBL] [Abstract][Full Text] [Related]
14. Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial.
Hillmen P; Eichhorst B; Brown JR; Lamanna N; O'Brien SM; Tam CS; Qiu L; Kazmierczak M; Zhou K; Šimkovič M; Mayer J; Gillespie-Twardy A; Shadman M; Ferrajoli A; Ganly PS; Weinkove R; Grosicki S; Mital A; Robak T; Österborg A; Yimer HA; Salmi T; Ji M; Yecies J; Idoine A; Wu K; Huang J; Jurczak W
J Clin Oncol; 2023 Feb; 41(5):1035-1045. PubMed ID: 36395435
[TBL] [Abstract][Full Text] [Related]
15. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Munir T; Brown JR; O'Brien S; Barrientos JC; Barr PM; Reddy NM; Coutre S; Tam CS; Mulligan SP; Jaeger U; Kipps TJ; Moreno C; Montillo M; Burger JA; Byrd JC; Hillmen P; Dai S; Szoke A; Dean JP; Woyach JA
Am J Hematol; 2019 Dec; 94(12):1353-1363. PubMed ID: 31512258
[TBL] [Abstract][Full Text] [Related]
16. Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma.
Tam CS; Opat S; Simpson D; Cull G; Munoz J; Phillips TJ; Kim WS; Rule S; Atwal SK; Wei R; Novotny W; Huang J; Wang M; Trotman J
Blood Adv; 2021 Jun; 5(12):2577-2585. PubMed ID: 34152395
[TBL] [Abstract][Full Text] [Related]
17. Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies.
Tam CS; Dimopoulos M; Garcia-Sanz R; Trotman J; Opat S; Roberts AW; Owen R; Song Y; Xu W; Zhu J; Li J; Qiu L; D'Sa S; Jurczak W; Cull G; Marlton P; Gottlieb D; Munoz J; Phillips T; Du C; Ji M; Zhou L; Guo H; Zhu H; Chan WY; Cohen A; Novotny W; Huang J; Tedeschi A
Blood Adv; 2022 Feb; 6(4):1296-1308. PubMed ID: 34724705
[TBL] [Abstract][Full Text] [Related]
18. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
Chanan-Khan A; Cramer P; Demirkan F; Fraser G; Silva RS; Grosicki S; Pristupa A; Janssens A; Mayer J; Bartlett NL; Dilhuydy MS; Pylypenko H; Loscertales J; Avigdor A; Rule S; Villa D; Samoilova O; Panagiotidis P; Goy A; Mato A; Pavlovsky MA; Karlsson C; Mahler M; Salman M; Sun S; Phelps C; Balasubramanian S; Howes A; Hallek M;
Lancet Oncol; 2016 Feb; 17(2):200-211. PubMed ID: 26655421
[TBL] [Abstract][Full Text] [Related]
19. Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.
Sharman JP; Brander DM; Mato AR; Ghosh N; Schuster SJ; Kambhampati S; Burke JM; Lansigan F; Schreeder MT; Lunin SD; Zweibach A; Shtivelband M; Travis PM; Chandler JC; Kolibaba KS; Sportelli P; Miskin HP; Weiss MS; Flinn IW
Lancet Haematol; 2021 Apr; 8(4):e254-e266. PubMed ID: 33631112
[TBL] [Abstract][Full Text] [Related]
20. Health-related quality-of-life in treatment-naive CLL/SLL patients treated with zanubrutinib versus bendamustine plus rituximab.
Ghia P; Barnes G; Yang K; Tam CS; Robak T; Brown JR; Kahl BS; Tian T; Szeto A; Paik JC; Shadman M
Curr Med Res Opin; 2023 Sep; ():1-7. PubMed ID: 37752878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
